AMRN
Amarin Corporation plc
AMRN trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over AMRN overall, supported by stronger fundamentals and stronger modeled upside.
AMRN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Strong | |
| Unavailable |
AMRN's cash flow is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMRN PE Valuation
AMRN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AMRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Weakening | |
| Limited | |
| High |
Analysts expect AMRN's losses to grow, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AMRN on the outlook, with more favorable earnings and revenue expectations.
AMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$3.20 |
| Q2 2026 | -$0.07 | +$4.36 |
| Q1 2026 | -$0.08 | +$4.32 |
| Q4 2025 | -$0.85 | +$3.15 |
| Q3 2025 | -$3.25 | -$1.25 |
| Q2 2025 | -$4.43 | -$2.63 |
| Q1 2025 | -$4.40 | -$1.80 |
| Q4 2024 | -$4.00 | -$1.00 |
AMRN is still losing money, but far less than before: $0.05 per share over the past year, against $5.36 at its worst in late 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AMRN on earnings quality, reporting a profit while its opponent remains loss making.
AMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $39.6M | -20% |
| Q2 2026 | $42.2M | -42% |
| Q1 2026 | $45.1M | +7.4% |
| Q4 2025 | $49.2M | -21% |
| Q3 2025 | $49.7M | +17% |
| Q2 2025 | $72.7M | +7.8% |
| Q1 2025 | $42M | -26% |
| Q4 2024 | $62.3M | -17% |
AMRN's revenue has slid since its 2020 peak: $40M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6% | +16 points |
| Q2 2026 | -28% | -6.5 points |
| Q1 2026 | -25% | +15 points |
| Q4 2025 | -13% | +72 points |
| Q3 2025 | -22% | +37 points |
| Q2 2025 | -22% | -21 points |
| Q1 2025 | -40% | -16 points |
| Q4 2024 | -84% | -78 points |
AMRN's operating margin was −6% last quarter, up 16 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AMRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AMRN on profitability, with a higher operating margin.
AMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.2M | +$21.9M |
| Q2 2026 | $6.6M | -60% |
| Q1 2026 | $6.4M | +$18.8M |
| Q4 2025 | $15.3M | +$28.6M |
| Q3 2025 | -$12.7M | -$10.3M |
| Q2 2025 | $16.6M | +$19.4M |
| Q1 2025 | -$12.5M | +$142K |
| Q4 2024 | -$13.3M | -$12.7M |
AMRN's free cash flow has turned positive after two years mostly in the red: $37M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AMRN on cash flow, with more consistent year-over-year improvement.
AMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +11.4M shares |
| 1 year | +3% | +12.3M shares |
| 3 years | +1995% | +407M shares |
| 5 years | +2058% | +408M shares |
| Available history | +2398% | +411M shares |
AMRN has 428M diluted shares, up 3% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AMRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AMRN Net Leverage
AMRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 13.7 | Oversold |
AMRN's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AMRN PE vs Healthcare Sector
AMRN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.0 | 2.8% below |
| 20 week MA | $13.3 | 12% below |
| 50 week MA | $14.2 | 18% below |
| 100 week MA | $13.7 | 15% below |
| 200 week MA | $16.8 | 31% below |
AMRN is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AMRN on trend strength, trading above more of its moving averages.
AMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $431.0 | $100.2 | -77% |
| 2021 | $100.2 | $70.2 | -30% |
| 2022 | $70.2 | $25.0 | -64% |
| 2023 | $25.0 | $17.4 | -30% |
| 2024 | $17.4 | $8.96 | -49% |
| 2025 | $8.96 | $14.1 | +58% |
| 2026 YTD | $14.1 | $11.7 | -17% |
AMRN has finished lower in five of the last six years. It's down 17% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AMRN on returns for 2026, with the stronger performance.